Pharmacogenomics at the point of prescribing
A plain-language guide for prescribers: what pharmacogenomics (PGx) is, how CPIC turns a patient's genotype into an actionable prescribing recommendation, and where gene-drug decision support fits into the e-prescribing workflow.
What pharmacogenomics changes about prescribing
Two patients on the same dose of the same drug can respond very differently. Part of that variation is inherited: genes that encode drug-metabolizing enzymes and transporters differ from person to person, changing how much active drug reaches its target. Pharmacogenomics (PGx) is the study of those inherited differences and how to act on them at the moment a prescription is written.
The practical value of PGx is not the raw genotype — it is a prescribing decision: choose a different drug, adjust the starting dose, or monitor more closely. That decision is most useful before the prescription is signed, not discovered later in a chart review.
CPIC: from genotype to a recommendation
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes peer-reviewed, freely available guidelines that translate a gene result into a specific therapeutic recommendation. Each guideline maps a patient's genotype to a metabolizer phenotype, then to guidance a prescriber can apply. CPIC guidelines are the standing reference used by clinical decision-support systems, including Telesphoros.
Metabolizer phenotypes, in brief
- Poor metabolizer (PM)
- Little or no enzyme activity. For a drug that needs activation, less active drug is formed; for a drug that is cleared by the enzyme, drug can accumulate.
- Intermediate (IM)
- Reduced activity, between poor and normal.
- Normal metabolizer (NM)
- Expected activity — standard dosing usually applies.
- Rapid / ultrarapid (RM / UM)
- Increased activity. For a prodrug, more active drug is formed, which can raise toxicity risk.
One caution: a patient's observed phenotype can differ from their genotype when an interacting drug inhibits the same enzyme — a phenomenon called phenoconversion. Good decision support accounts for concurrent medications, not genotype alone.
Three worked examples
These are among the best-established gene-drug pairs. Each links to the current CPIC guideline; always check the live guideline for the exact recommendation and covered alleles.
| Gene × drug | What the phenotype changes | Typical CPIC-guided action |
|---|---|---|
CYP2C19 × clopidogrel |
Clopidogrel is a prodrug activated by CYP2C19. Intermediate and poor metabolizers form less active drug, get less platelet inhibition, and carry higher risk of major adverse cardiovascular and cerebrovascular events.1 | Consider an alternative antiplatelet (e.g. prasugrel or ticagrelor) where appropriate.1 |
CYP2D6 × codeine / tramadol |
Both are activated by CYP2D6. Poor metabolizers get little analgesia; ultrarapid metabolizers form more active opioid, raising the risk of toxicity.2 | Avoid codeine/tramadol in poor and ultrarapid metabolizers; use an analgesic not dependent on CYP2D6.2 |
DPYD × 5-fluorouracil / capecitabine |
DPD (encoded by DPYD) clears fluoropyrimidines. Decreased-function variants slow clearance and sharply raise the risk of severe, sometimes fatal, toxicity.3 | Reduce the starting dose or select an alternative agent per genotype-guided dosing.3 |
Where this fits in e-prescribing
PGx guidance is only useful if it reaches the prescriber at the right moment. In Telesphoros, gene-drug checks fire at signing — the point where the choice can still change — and are phenoconversion-aware, so concurrent medications are considered alongside genotype. A check can block, warn, or inform depending on severity, and the genomic result is stored so it follows the patient to the next prescription rather than being re-ordered.
Pharmacogenomic checks are clinical decision support. Nutrigenomic findings, where offered, are advisory only and are not a prescribing gate.
This page is educational and does not replace clinical judgment or the current, complete CPIC guidelines. Recommendations are summarized and may not reflect the latest updates; consult the live guideline (linked below) and applicable product labeling before making prescribing decisions. Telesphoros supports non-controlled e-prescribing (US & Puerto Rico, Phase 1).
References
Citations below were verified against PubMed; each links to its DOI. CPIC guidelines are maintained at cpicpgx.org and gene-drug evidence is curated at PharmGKB.
- Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959–967. doi:10.1002/cpt.2526
- Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888–896. doi:10.1002/cpt.2149
- Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210–216. doi:10.1002/cpt.911